This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n12http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/kegg-drug/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/drugbank/
n20http://linked.opendata.cz/resource/mesh/concept/
n7http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/chemspider/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01092/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01092
rdf:type
n3:Drug
n3:description
A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. [PubChem]
n3:generalReferences
# Gao J, Wymore RS, Wang Y, Gaudette GR, Krukenkamp IB, Cohen IS, Mathias RT: Isoform-specific stimulation of cardiac Na/K pumps by nanomolar concentrations of glycosides. J Gen Physiol. 2002 Apr;119(4):297-312. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11929882 # Saunders R, Scheiner-Bobis G: Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. Eur J Biochem. 2004 Mar;271(5):1054-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15009217 # Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6259-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1648735 # Hamlyn JM, Laredo J, Shah JR, Lu ZR, Hamilton BP: 11-hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann N Y Acad Sci. 2003 Apr;986:685-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12763919 # Laredo J, Hamilton BP, Hamlyn JM: Ouabain is secreted by bovine adrenocortical cells. Endocrinology. 1994 Aug;135(2):794-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8033829
n3:group
approved
n3:indication
For the treatment of atrial fibrillation and flutter and heart failure
owl:sameAs
n6:DB01092 n7:DB01092
dcterms:title
Ouabain
adms:identifier
n12:46505479 n13:D00112 n14:439501 n15:DB01092 n16:C01443 n17:472805 n18:388599 n21:PA163522138 n22:Ouabain
n3:mechanismOfAction
Ouabain inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Ouabain also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
n3:synonym
Oubain Strodival Ouabagenin L-Rhamnoside Ouabagenin-L-rhamnosid Ouabain 3-(alpha-L-Rhamnopyranosyloxy)-1beta,5beta,11alpha,14,19-pentahydroxy-5beta-card-20(22)-enolide G-Strophanthin Ouabaine Ouabain anhydrous
n3:proteinBinding
60%
n19:hasConcept
n20:M0015582
n3:IUPAC-Name
n4:271B64D2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B64D8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B64D7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B64D4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B64D5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B64D6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B64D0-363D-11E5-9242-09173F13E4C5 n4:271B64E8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B64D1-363D-11E5-9242-09173F13E4C5 n4:271B64CE-363D-11E5-9242-09173F13E4C5 n4:271B64EA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B64CF-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:C01AC01
n3:H-Bond-Acceptor-Count
n4:271B64DE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B64DF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B64D9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B64DA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B64DC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B64DB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B64DD-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
630-60-4
n3:category
n3:Bioavailability
n4:271B64E4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B64E6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B64E7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B64E9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B64E3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B64E2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B64E5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B64D3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B64E0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B64E1-363D-11E5-9242-09173F13E4C5